The eight pharmaceutical companies that were warned by the Federal Trade Commission (FTC) in April about potentially improper patent listings in a crucial federal database have opted not to remove or alter any patents. This decision comes despite the FTC’s concerns about the accuracy and appropriateness of these listings, as detailed in a document released on June 21, 2024.
For more information, refer to the document available at Law360.